US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
biotech · Head and Neck Cancer · Solid Tumor · PPBT
PURPLE BIOTECH
PURPLE BIOTECH LTD.
PURPLE BIOTECH drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
REHOVOT, L3, USA HQ
2010 Founded
12 Employees
Public company Type
PPBT · NYSE Ticker
Company details
- Status
- Public
- HQ
- REHOVOT, L3, USA
- Founded
- 2010
- Employees
- 12
- Programs
- 3
- Drugs
- 4
- Patents
- 3
PURPLE BIOTECH pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
PURPLE BIOTECH drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to PURPLE BIOTECH in public FDA and regional records.
-
Development asset linked to PURPLE BIOTECH in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor